Antibodies News and Research

RSS

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many covid experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country's objectives in its fight against the coronavirus.

21 Mar 2022

Study assesses human milk antibodies against common human coronaviruses following COVID-19 infection and vaccination

A recent study demonstrated that COVID-19 and its vaccination generates cross-reactive antibodies against human coronaviruses in lactating mothers.

21 Mar 2022

Biological timeline of COVID-19 immune recovery described in new research

In a recent study published on the bioRxiv* preprint server, a group of researchers from the University of California, San Francisco, looked at intra-patient immunological changes over time to see if there were any changes in immune responses associated with successful COVID-19 resolution.

21 Mar 2022

Substantial alteration in gut microbiome observed in children with with MIS-C and COVID

A team of scientists from Turkey has recently evaluated the diversity and composition of gut microbiota in children diagnosed with multisystem inflammatory syndrome (MIS-C) and acute coronavirus disease 2019 (COVID-19). They have observed significant alteration in the gut microbiota composition in children with MIS-C. These changes are associated with autoimmunity, metabolic dysfunction, and obesity.

21 Mar 2022

Antibodies News and Research

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

Study assesses human milk antibodies against common human coronaviruses following COVID-19 infection and vaccination

Biological timeline of COVID-19 immune recovery described in new research

Substantial alteration in gut microbiome observed in children with with MIS-C and COVID

Sex-specific differences in T-cell responses to COVID-19

Cov2clusters: Novel method for producing stable genomic clusters of SARS-CoV-2 cases

Omicron BA.1.1 and BA.2 subvariants with new mutations in New Zealand and Hong Kong

Natural circulating antibodies last for at least seven months in children infected with COVID-19

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

Covalent protein nanobodies for neutralizing SARS-CoV-2 and its variants

Neutrophils found to initiate COVID-19-associated olfactory epithelial damage in hamsters

Innate and adaptive immune responses to BNT162b2 vaccination in mice

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

SARS-CoV-2 burden and transmission in one rural and one urban community in South Africa

COVID-19-related hospitalization among infants and young children in the US

Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

Why does the SARS-CoV-2 Omicron variant escape immunity?

Immuno-metabolomic signatures that correlate with antigen-specific-T cell response during active COVID-19

Impact of new COVID vaccinations as novel variants emerge

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News